Cipla, Cadila Health, Natco Pharma top picks: AnandRathi

AnandRathi has come out with its report on India healthcare. According to the research firm, EBITDA margins are expected to be stable at 22-23 percent during the quarter. Cipla, Cadila Healthcare, Natco Pharma, and Unichem Laboratories are the top picks, says AnandRathi.
  • Language
  • App
  • Subscriptions
  • Specials
  • Sign-In
  • Register
GeStepAhead GrowMyMoney
moneycontrol.com

Home » News » Brokerage Recos - Sector Report

Jul 09, 2013, 07.23 PM | Source: Moneycontrol.com

Cipla, Cadila Health, Natco Pharma top picks: AnandRathi

AnandRathi has come out with its report on India healthcare. According to the research firm, EBITDA margins are expected to be stable at 22-23 percent during the quarter. "Cipla, Cadila Healthcare, Natco Pharma, and Unichem Laboratories are the top picks, says AnandRathi.

Like this story, share it with millions of investors on M3

Cipla, Cadila Health, Natco Pharma top picks: AnandRathi

AnandRathi has come out with its report on India healthcare. According to the research firm, EBITDA margins are expected to be stable at 22-23 percent during the quarter. "Cipla, Cadila Healthcare, Natco Pharma, and Unichem Laboratories are the top picks, says AnandRathi.

Post Your Comments

Share Cancel

(more)

, AnandRathi |

India Healthcare - Exports to drive revenues, says AnandRathi

Revenue growth to take a hit: Companies under our coverage are likely to post 9.4 percent yoy revenue growth, lower than high double-digit growth in the  past few quarters due to slowdown in domestic industry with implementation of new drug pricing policy and high base because of FTFs. However, exports (ex FTFs) would remain strong with ~20 percent growth. Excluding FTFs, we expect overall 14.3 percent revenue growth during the quarter. Sun, Lupin, Glenmark, DRL, and Ipca are expected to drive most of the revenue growth.

Margin stable, adj. PAT higher: We expect EBITDA margins to be stable at 22-23 percent during the quarter. However, ex the impact of Lipitor exclusivity for Ranbaxy in 1QFY13, we estimate 100bps improvement in EBITDA margin. Adjusted PAT growth could be 10.9 percent yoy, higher than revenue growth due to higher other income and reduced interest cost. Sun , DRL , Lupin , Glenmark , Pfizer and Ipca would register higher net profit growth.

Domestic business may surprise negatively: Considering AIOCD AWACS data, domestic pharma industry has grown at single digit in Apr- May'13 against mid teens in the past few years. The slowdown has been across therapeutic categories, including chronic. Further, implementation of new drug pricing policy could also hit growth.

Our take: Led by strong revenues in export formulations and stable margin, we expect continued momentum in India healthcare. Domestic formulations may surprise negatively in FY14e due to new drug pricing policy. We remain Overweight on the sector.

Top picks:  Cipla , Cadila Healthcare , Natco Pharma , and Unichem Laboratories .

Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on moneycontrol.com are their own, and not that of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.

To read the full report click here

Buy, Hold, Sell ? Hear it first on M3
Cipla, Cadila Health, Natco Pharma top picks: AnandRathi

See all

Get started using your favorite social network

or

Login using moneycontrol ID

Username
Password

Need help logging in? Reset password.

Don´t have an account? Sign Up

Get started using your favorite social network

or

Simply sign up using this short form

* mandatory

UserName*

Username should be atleast 4 character

Password*

Password should be 8 or more characters,
atleast 1 number, 1 symbol & 1 upper case letter

Alert

Your Password should contain
  • 8 or more characters
  • At least 1 number
  • At least 1 symbol
  • At least 1 upper case letter
Confirm Password*
Email
Already have an account? Login